The billionaire majority owner of Insys Therapeutics was arrested Thursday over allegations of using bribes and fraud to distribute a powerful cancer drug to non-cancer patients.

Subsys, a type of fentanyl spray, produced effects that were practically indistinguishable from those produced by the opioids morphine and heroin, according to an indictment.

John Kapoor, the majority owner and former chairman and CEO, was arrested Thursday as President Donald Trump unveiled his anti-opioid addiction efforts. Kapoor and six former executives also were alleged to have defrauded health insurance providers who were reluctant to approve payment for the drug when it was prescribed for non-cancer patients.

Kapoor’s attorney didn’t return a message. Kapoor had stepped down as CEO in January but stayed on the board.

Insys Therapeutics US:INSY stock ended 23% lower on Thursday.

“In the midst of a nationwide opioid epidemic that has reached crisis proportions, Mr. Kapoor and his company stand accused of bribing doctors to overprescribe a potent opioid and committing fraud on insurance companies solely for profit,” said Acting United States Attorney William D. Weinreb in a statement.

According to Forbes, Kapoor was worth as much as $3.3 billion, and was number 335 on the Forbes 400 list in 2016.

The indictment tells of efforts to prescribe the drug at higher and higher doses to people who didn’t need them and to avoid Drug Enforcement Administration detection efforts.

Alec Burlakoff, the company’s former vice president of sales and one of six other executives who previously were charged, was quoted telling the sales force at a 2014 meeting:

[T]hese [doctors] will tell you all the time, well, I’ve only got like eight patients with cancer. Or, I only have, like, twelve patients that are on a rapid-onset opioids [sic]. Doc, I’m not talking about any of those patients. I don’t want any of those patients. That’s, that’s small potatoes. That’s nothing. That’s not what I’m here doing. I’m here selling [unintelligible] for the breakthrough pain. If I can successfully sell you the [unintelligible] for the breakthrough pain, do you have a thousand people in your practice, a thousand patients, twelve of them are currently on a rapid-onset opioids [sic]. That leaves me with at least five hundred patients that can go on this drug.

At another sales meeting, Burlakoff and other reps used a video set to an A$AP Rocky rap to promote higher dosing. “I love titration, and that’s not a problem,” the sales reps sung while dancing with a life-sized bottle, according to the indictment. Titration is the process by which patients were switched to the fentanyl spray.

A Congressional investigation has previously found that Insys emphasized using the drug for off-label uses. “Evidence from our investigation suggests that Insys was engaged in systemic fraud and took actions that directly harmed their own customers and public health as a whole,” said Sen. Claire McCaskill, a Missouri Democrat, in a statement.